Evaluation of the Value of Multiplex MicroRNA Analysis as a Breast Cancer Screening in Korean Women under 50 Years of Age with a High Proportion of Dense Breasts.

IF 2.5 Q3 ONCOLOGY
Ji Young Jang, Eun Young Ko, Ji Soo Jung, Kyung Nam Kang, Yeon Soo Kim, Chul Woo Kim
{"title":"Evaluation of the Value of Multiplex MicroRNA Analysis as a Breast Cancer Screening in Korean Women under 50 Years of Age with a High Proportion of Dense Breasts.","authors":"Ji Young Jang,&nbsp;Eun Young Ko,&nbsp;Ji Soo Jung,&nbsp;Kyung Nam Kang,&nbsp;Yeon Soo Kim,&nbsp;Chul Woo Kim","doi":"10.15430/JCP.2021.26.4.258","DOIUrl":null,"url":null,"abstract":"<p><p>This study was conducted to confirm the performance of the microRNA (miRNA) biomarker combination as a new breast cancer screening method in Korean women under the age of 50 with a high percentage of dense breasts. To determine the classification performance of a set of miRNA biomarkers (miR-1246, 202, 21, and 219B) useful for breast cancer screening, we determined whether there was a significant difference between the breast cancer and healthy control groups through box plots and the Mann-Whitney U-test, which was further examined in detail by age group. To verify the classification performance of the 4 miRNA biomarker set, 4 classification methods (logistic regression, random forest, XGBoost, and generalized linear model plus random forest) were applied, and 10-fold cross-validation was used as a validation method to improve performance stability. We confirmed that the best breast cancer detection performance was achievable in patients under 50 years of age when the set of 4 miRNAs were used. Under the age of 50, the 4 miRNA biomarkers showed the highest performance with a sensitivity of 85.29%, specificity of 93.33%, and area under the curve (AUC) of 0.961. Examining the results of 4 miRNA biomarkers was found to be an effective strategy for diagnosing breast cancer in Korean women under 50 years of age with dense breasts, and hence has the potential as a new breast cancer screening tool. Further validation in an appropriate screening population with large-scale clinical trials is required.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"26 4","pages":"258-265"},"PeriodicalIF":2.5000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/d5/jcp-26-4-258.PMC8749312.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2021.26.4.258","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

This study was conducted to confirm the performance of the microRNA (miRNA) biomarker combination as a new breast cancer screening method in Korean women under the age of 50 with a high percentage of dense breasts. To determine the classification performance of a set of miRNA biomarkers (miR-1246, 202, 21, and 219B) useful for breast cancer screening, we determined whether there was a significant difference between the breast cancer and healthy control groups through box plots and the Mann-Whitney U-test, which was further examined in detail by age group. To verify the classification performance of the 4 miRNA biomarker set, 4 classification methods (logistic regression, random forest, XGBoost, and generalized linear model plus random forest) were applied, and 10-fold cross-validation was used as a validation method to improve performance stability. We confirmed that the best breast cancer detection performance was achievable in patients under 50 years of age when the set of 4 miRNAs were used. Under the age of 50, the 4 miRNA biomarkers showed the highest performance with a sensitivity of 85.29%, specificity of 93.33%, and area under the curve (AUC) of 0.961. Examining the results of 4 miRNA biomarkers was found to be an effective strategy for diagnosing breast cancer in Korean women under 50 years of age with dense breasts, and hence has the potential as a new breast cancer screening tool. Further validation in an appropriate screening population with large-scale clinical trials is required.

Abstract Image

Abstract Image

Abstract Image

多重MicroRNA分析在韩国50岁以下高密度乳房高发女性乳腺癌筛查中的价值评价
这项研究是为了确认microRNA (miRNA)生物标志物组合作为一种新的乳腺癌筛查方法,在50岁以下乳房密度高的韩国女性中发挥作用。为了确定对乳腺癌筛查有用的一组miRNA生物标志物(miR-1246、202、21和219B)的分类性能,我们通过箱形图和Mann-Whitney u检验确定乳腺癌组与健康对照组之间是否存在显著差异,并进一步按年龄组详细检查。为了验证4个miRNA生物标志物集的分类性能,我们采用了4种分类方法(逻辑回归、随机森林、XGBoost和广义线性模型加随机森林),并采用10倍交叉验证作为验证方法,以提高性能稳定性。我们证实,当使用这4组mirna时,在50岁以下的患者中可以实现最佳的乳腺癌检测性能。在50岁以下人群中,4种miRNA生物标志物的敏感性最高,灵敏度为85.29%,特异性为93.33%,曲线下面积(AUC)为0.961。研究结果显示,检测4种miRNA生物标志物是诊断50岁以下乳房致密的韩国女性乳腺癌的有效策略,因此有可能成为新的乳腺癌筛查工具。需要在适当的筛查人群中进行大规模临床试验进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
4.00%
发文量
32
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信